Effects of Different Acupuncture Techniques on the Success Rate in Patients With Recurrent Implantation Failure

June 20, 2026 updated by: Cui Hong Zheng
To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of different acupuncture methods on the success rate in patients with recurrent implantation failure

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

312

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos).
  2. Age: 20 to 40 years old.
  3. Planning for a cycle involving the transfer of frozen-thawed embryos (FET).
  4. Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC).
  5. Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation.

Exclusion Criteria:

  1. Individuals planning to undergo preimplantation genetic diagnosis (PGD).
  2. Recipients of egg donations.
  3. Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).
  4. Patients with known embryo-related factors leading to implantation failure.
  5. Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).
  6. Abnormalities in immunity and blood coagulation
  7. Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more).
  8. Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months.
  9. Individuals with untreated hydrosalpinx;
  10. Individuals with a Body Mass Index (BMI) below 18 and above 25 kg/ m2.
  11. Men with severe abnormalities in semen quality. Individuals with a history of needle phobia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: placebo acupuncture group
nonpenetrating placebo needles
Device: Placebo Group
nonpenetrating placebo needles
Experimental: acupuncture group 1
indwelling intradermal needles
Device: acupuncture group 1
indwelling intradermal needles
Experimental: acupuncture group 2
combining fire needle and regular acupuncture
Device: acupuncture group 2
combining fire needle and regular acupuncture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
clinical pregnancy
Time Frame: 2 years
defined as ultrasonographic detection of an intrauterine gestational sac following embryo transfer
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
β-hCG-positive pregnancy
Time Frame: 2 years
defined as serum β-hCG concentration >10 mIU/mL on day 14 post-transfer
2 years
live birth
Time Frame: 3 years
defined as the delivery of 1 or more living infants at greater than 20 weeks' gestation or birth weight of at least 400 g
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cui Hong Zheng

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

June 30, 2029

Study Registration Dates

First Submitted

June 20, 2026

First Submitted That Met QC Criteria

June 20, 2026

First Posted (Actual)

June 25, 2026

Study Record Updates

Last Update Posted (Actual)

June 25, 2026

Last Update Submitted That Met QC Criteria

June 20, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • TJ-IRB202605092

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Implantation Failure

Clinical Trials on Placebo Group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe